Combined Hormonal Contraceptives for Ovulatory Dysfunction Bleeding

Primary Treatment Approach

• The American College of Obstetricians and Gynecologists (ACOG) guidelines recommend combined hormonal contraception as a medical treatment option for abnormal uterine bleeding associated with ovulatory dysfunction in reproductive-age women, with the choice depending on contraceptive needs and tolerability rather than bleeding control 1, 2, 3
• The ACOG guidelines do not specify a particular CHC type or estrogen/progestin dose to use for treating ovulatory dysfunction bleeding, as all CHC methods work through the same mechanism of endometrial stabilization and cycle regulation 1

Clinical Decision-Making Algorithm

• The American College of Obstetricians and Gynecologists (ACOG) recommends starting with any standard CHC formulation based on patient preference and medical eligibility for treating ovulatory dysfunction bleeding 1, 2
• Pregnancy should be excluded before initiating CHC treatment for ovulatory dysfunction bleeding, as recommended by ACOG 1, 2
• Structural pathologies and endometrial disease should be ruled out through appropriate evaluation before initiating CHC treatment for ovulatory dysfunction bleeding, as recommended by ACOG 1, 3
• The U.S. Medical Eligibility Criteria for Contraceptive Use should be used to verify no contraindications exist for CHC treatment in patients with ovulatory dysfunction bleeding 4

Alternative Considerations

• If the patient requires contraception, CHCs are a particularly appropriate treatment option for ovulatory dysfunction bleeding, according to ACOG 1
• Cyclic progestin therapy is an alternative medical option for treating ovulatory dysfunction bleeding in patients who do not require contraception or have contraindications to CHCs 1
• Surgical options, such as endometrial ablation or hysterectomy, are reserved for cases where medical treatment fails, is contraindicated, or is not tolerated for ovulatory dysfunction bleeding 1, 2